This study confirms that tirzepatide reduces the expression of CD36 and OBP2A, thereby decreasing lipid uptake, which appears to be the primary mechanism underlying its alleviation of intrahepatic lipid accumulation in MASLD. Here, CD36 is linked to metabolic dysfunction-associated steatotic liver disease.